Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11932661 | 0.86 | CSNK2A1 (0.45) | EGFRCSNK2A1CSNK2A2CSNK2BABCG2 | |
| SCHEMBL13688023 | 0.85 | CSNK2A1 (0.44) | EGFRCSNK2A1CSNK2A2CSNK2BABCG2 | |
| SCHEMBL10134763 | 0.84 | CSNK2A1 (0.46) | EGFRCSNK2A1CSNK2A2CSNK2BABCG2 | |
| SCHEMBL13688029 | 0.83 | EGFR (0.58) | EGFRCSNK2A1CSNK2A2CSNK2BABCG2 | |
| SCHEMBL13688025 | 0.81 | EGFR (0.60) | EGFRCSNK2A1CSNK2A2CSNK2BABCG2 | |
| SCHEMBL10134772 | 0.79 | CSNK2A1 (0.51) | EGFRCSNK2A1CSNK2A2CSNK2BABCG2 | |
| SCHEMBL13688039 | 0.75 | EGFR (0.61) | EGFRCSNK2A1CSNK2A2CSNK2BABCG2 | |
| SCHEMBL13688035 | 0.72 | MDM4 (0.42) | EGFRKDR | |
| SCHEMBL29923578 | 0.70 | EGFR (1.00) | EGFRGRM1KDRBRAF | |
| SCHEMBL31299934 | 0.70 | EGFR (1.00) | EGFRGRM1KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | EGFR 580/4885CSNK2A1 680/4885CSNK2A2 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.